Sat.Jul 06, 2024 - Fri.Jul 12, 2024

article thumbnail

FTC said to be planning legal action against PBMs

pharmaphorum

The FTC is said to be gearing up to file lawsuits against the top three pharmacy benefit managers in the wake of its damning report on the sector.

article thumbnail

Senate unanimously endorses legislation targeting pharma 'patent thickets'

Fierce Pharma

Even as pharma companies have yet to feel the full effects of the Inflation Reduction Act, Senate lawmakers have turned their attention to another facet of drug pricing with a bill meant to cr | The bill looks to limit the number of patents that companies can assert in litigation on individual products. It's intended to crack down on "patent thickets," which can delay and thwart generic competition.

Pharma 325
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Clarivate launches Academia AI Advisory Council

Clarivate

“AI Everywhere All at Once.” This year’s theme from Outsell, Inc. perfectly captures the expansion of artificial intelligence across all facets of our lives. In academia, this rapid advancement raises more questions than answers. How do we ensure ethical AI use? How can we advance research and drive research integrity? How do we use AI to advance student learning skills?

Ethics 122
article thumbnail

Health Leaders Applaud HHS’ Action Giving Some Incarcerated Individuals Medicaid Coverage Before Release

MedCity News

Illinois, Kentucky, Oregon, Utah and Vermont have been authorized by HHS to provide Medicaid/Children’s Health Insurance Program coverage to those transitioning out of incarceration up to 90 days before they’re released. Several healthcare leaders called the action a necessary step. The post Health Leaders Applaud HHS’ Action Giving Some Incarcerated Individuals Medicaid Coverage Before Release appeared first on MedCity News.

Insurance 119
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Bill that would cut down ‘patent thickets’ clears Senate

pharmaphorum

The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.Lawmakers unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150), which is part of a lengthening list of measures being taken by Congress to curb the prices of medicines in the US.

article thumbnail

Lilly's Mounjao triggers more weight loss than Novo Nordisk's Ozempic: study

Fierce Pharma

Is Eli Lilly’s Mounjaro or Novo Nordisk’s Ozempic more effective in helping patients lose weight? | Is Eli Lilly’s Mounjaro or Novo Nordisk’s Ozempic more effective in helping patients lose weight? While a head-to-head trial pitting the two treatments remains ongoing, new evidence shows that Lilly’s tirzepatide may be the superior weight loss product.

Patients 317

More Trending

article thumbnail

With New Huntington’s Gene Therapy Data, uniQure Hopes for Faster Path With FDA

MedCity News

A uniQure gene therapy for Huntington’s disease has interim clinical data showing an 80% slowing of disease progression. An accelerated approval pathway is one of the topics the company wants to discuss with the FDA. The post With New Huntington’s Gene Therapy Data, uniQure Hopes for Faster Path With FDA appeared first on MedCity News.

FDA 117
article thumbnail

Agios Pharmaceuticals’ “Do You See It?” Campaign Featured in MM+M

Eversana Intouch

MM+M recently named Agios Pharmaceuticals’ “Do You See It?” campaign as their Campaign of the Week! The campaign focuses on the hidden dangers of thalassemia, a rare genetic condition affecting an estimated 8,000 Americans. The disease can result in anemia-like symptoms, with severe cases requiring regular blood transfusions, while milder cases often go untreated.

article thumbnail

Novo Nordisk's Ozempic cuts dementia risk compared with Merck's Januvia: Oxford study

Fierce Pharma

Trials have already shown that Novo Nordisk’s semaglutide | Trials have already shown that Novo Nordisk’s semaglutide can cut the risk of cardiovascular events and kidney disease. Now a study from the University of Oxford indicates that the company’s semaglutide type 2 diabetes drug Ozempic can reduce the risk of dementia compared with another popular diabetes medicine.

Medicine 299
article thumbnail

Chromatography analysis for nitrosamine quantitation in pharmaceutical manufacturing water

European Pharmaceutical Review

Researchers have developed an ultrasensitive analytical method for quantifying nitrite quantity in process water for pharmaceutical products. The team tested various samples two ion chromatography analytical methods. This included a range of water types eg, purified and potable water, according to the paper. Kumar et al. explained that “accurate determination of nitrite content in process water will support an understanding of the potential for nitrosamine formation from nitrite in process water

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Closing the Gap in Medications for the Treatment of Alcohol Use Disorder (AUD)

MedCity News

By understanding that AUD is a diagnosable and treatable medical condition with individualized impact, we can tailor treatments to meet patients’ specific needs. Effective treatment for AUD is multifaceted, involving medical, psychological, and social support. The post Closing the Gap in Medications for the Treatment of Alcohol Use Disorder (AUD) appeared first on MedCity News.

Medical 111
article thumbnail

The Current Landscape of Drug Shortages

Pharmaceutical Commerce

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth, founder and CEO, offers his thoughts surrounding the lack of supply.

Pharma 105
article thumbnail

The end of the beginning: Lilly execs eye top spot in burgeoning Alzheimer's market after Kisunla's FDA approval

Fierce Pharma

Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease market is set to grow in earnest—and Lilly is already eyeing a spot at the t | On top of Eisai and Biogen's Leqembi, Kisunla’s approval likely marks the “end of the beginning in treating this disease,” Andrew Lechleiter, VP of U.S.

Marketing 290
article thumbnail

Own Your Career: Intentional Professional Development

ALULA

Earlier this year, I had the pleasure of giving an invited talk at the Organizational Behavior Management ( OBM ) Network Conference in Houston, TX. I knew it would be a great opportunity to engage with OBM professionals and researchers on a challenge that everyone shares right now: facing the inevitability of change, particularly career change.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Will A Divestiture Save the UnitedHealth Group-Amedisys Deal?

MedCity News

Amedisys and UnitedHealth Group plan to divest care centers to an affiliate of VitalCaring Group. Several experts said this will likely clear the way for the companies’ merger. The post Will A Divestiture Save the UnitedHealth Group-Amedisys Deal? appeared first on MedCity News.

111
111
article thumbnail

Pfizer research chief Dolsten to step down, with company at a crossroads

PharmaVoice

The company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and vaccine approvals alongside notable setbacks during his time as Pfizer’s top scientist.

98
article thumbnail

Move over, oncology: Obesity, diabetes meds will take over 2030's top drug rankings, Evaluate forecasts

Fierce Pharma

It’s well known that obesity drugs from Novo Nordisk and Eli Lilly are on a high-flying growth trajectory that doesn’t look to be letting up anytime soon. | Novo Nordisk's Ozempic is slated to take over No.1, while Merck's Keytruda falls to No.9 on Evaluate's predicted rankings of top drugs by 2030 sales.

Sales 277
article thumbnail

Medical Sales Rep Recruitment (Part 2): How to optimize the hiring process to select top talent.

MaBiCo

Medical Sales Rep Recruitment (Part 2): How to optimize the hiring process to select top talent. In our previous article, we explored the fundamental steps necessary for implementing an effective medical representative selection process. These steps included identifying key characteristics exhibited by top-performing salespeople and using them as benchmarks for hiring.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

A No-Go for HilleVax as Norovirus Vaccine Fails Mid-Stage Test in Infants

MedCity News

HilleVax’s norovirus vaccine failed a Phase 2b study in infants, but it’s not the end of the road for the biotech. A business deal this year brought HilleVax a Phase 1-ready norovirus vaccine candidate designed to offer even broader protection. The post A No-Go for HilleVax as Norovirus Vaccine Fails Mid-Stage Test in Infants appeared first on MedCity News.

Biopharma 104
article thumbnail

Cleanroom microbiology: single-temperature incubation for EM

European Pharmaceutical Review

Single- or mono-temperature incubation is not easy to implement, but it offers efficiency and performance advantages and an opportunity to simplify the process in a pharmaceutical microbiology laboratory. This article shares our motivations, approach and experience of implementing mono-temperature incubation in our laboratories over the past several years.

article thumbnail

Merck puts 1,000-plus Zostavax lawsuits to bed after plaintiffs file for dismissal

Fierce Pharma

After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax. | A U.S. appeals court has tossed a request to resurrect certain lawsuits claiming Merck’s popular shot Zostavax caused patients to develop shingles. The court made its decision after the plaintiffs filed a voluntary dismissal some two years after logging a loss in Pennsylvania.

Patients 268
article thumbnail

Proposed Medicare codes could lift digital health sector

pharmaphorum

A new payment policy proposal released by the Centers for Medicare and Medicaid Services (CMS) this week covers digital tools used for behavioural health, which could be a boost for the digital health sector.The Medicare Physician Fee Schedule (PFS) sets out the method of payment, rates, and codes for healthcare providers participating in Medicare, and is often used by the administration as an instrument to encourage some forms of healthcare intervention.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Streamlining Healthcare: How Technology is Removing Friction for Providers

MedCity News

Here’s a look at three innovative software solutions that support healthcare transformation and are having a significant impact. The post Streamlining Healthcare: How Technology is Removing Friction for Providers appeared first on MedCity News.

article thumbnail

Myricx Bio gains $114m in Series A round to develop NMTi-ADCs

Pharmaceutical Technology

Myricx Bio has secured £90m ($114m) in its Series A financing round to propel its NMTi-ADC therapeutics into the clinical development stage.

105
105
article thumbnail

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Fierce Pharma

After announcing plans last year to expand manufacturing in its home country, Korean CDMO newcomer Lotte Biologics has kicked off work on a sprawling facility along Incheon’s waterfront near Seoul. | Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 CDMOs in the world.

article thumbnail

BMS’ long-standing leukemia blockbuster stares down its first generic

PharmaVoice

Patent disputes in the U.S. and abroad have opened the door to new generics ready for launch as soon as September for BMS’ Sprycel.

105
105
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

How Can Hospitals Best Leverage Multi-Cancer Screening Tests? Providence Researchers Aim to Find Out

MedCity News

Providence recently launched a study to help learn more about how health systems can use multi-cancer detection tests in clinical care. Three years ago, Providence became the first health system to use Grail’s Galleri test, which screens patients for more than 50 kinds of cancer. The post How Can Hospitals Best Leverage Multi-Cancer Screening Tests?

Patients 104
article thumbnail

After FDA delay, Arcutis gets Zoryve OK in atopic dermatitis

pharmaphorum

After short but worrying delay, Arcutis gets FDA approval for flagship drug Zoryve in atopic dermatitis, which could further unlock sales growth

FDA 116
article thumbnail

Novo's Ozempic, Wegovy linked to potential eye problem? Not so fast, analysts say

Fierce Pharma

Novo Nordisk’s massively successful GLP-1 analog semaglutide, the active ingredient in the popular diabetes and obesity meds Ozempic and Wegovy, may be linked to a vision loss disorder, a new | Novo Nordisk’s popular GLP-1 analog semaglutide may be linked to a vision loss disorder, a study suggests. But one team of analysts cautioned against reading too much into the analysis.

254
254
article thumbnail

Could pharma’s blockbuster immunotherapies work in dogs?

PharmaVoice

Vetigenics believes it’s found a way to make pricey antibody-based technologies more accessible for animals.

111
111
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time